de Borja Callejas Francisco, Martínez-Antón Asunción, Picado César, Alobid Isam, Pujols Laura, Valero Antonio, Roca-Ferrer Jordi, Mullol Joaquim
Department of Clinical and Experimental Respiratory Immunoallergy, August Pi i Sunyer Biomedical Research Institute, University of Barcelona, Barcelona, Spain; Centers for Biomedical Research Network in Respiratory Diseases, Barcelona, Spain.
Laryngoscope. 2015 May;125(5):E158-67. doi: 10.1002/lary.25147. Epub 2015 Jan 13.
OBJECTIVES/HYPOTHESIS: To investigate the effect of oral plus intranasal corticosteroid (CS) treatment on nasal polyp (NP) mucosa remodeling from patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP). STUDY DESIGN: Case series, retrospective study. METHODS: Patients (n = 18) with severe CRSwNP were treated with oral prednisone for 2 weeks and intranasal budesonide for 12 weeks. NP biopsies were obtained from patients biopsies before (w0) and after 2 weeks (w2) and 12 weeks (w12) of CS treatment. Matrix metalloprotease 1 (MMP-1), MMP-2, MMP-7, MMP-9, and tissue inhibitor of metalloprotease type 1 (TIMP-1) expression was evaluated by immunohistochemistry in cell and tissue structures. Epithelial damage, eosinophil infiltration, and collagen content were also examined in NP tissues before and after CS treatment. RESULTS: Compared to w0: 1) oral plus intranasal CS significantly (P < .01) increased presence of submucosal glands at w2, decreased epithelial cell hyperplasia at w12, and decreased tissue eosinophilia at w2 and w12; 2) CS treatment significantly (P < .05) increased immunoreactivity for MMP-1 and MMP-2 in the epithelium at w2, but decreased immunoreactivity for MMP-9 in the epithelium at w2 and w12; 3) at w12, CS significantly (P < .05) reduced MMP-9 immunoreactive positivity and intensity in the extracellular matrix, while increasing total collagen amount in the extracellular matrix; and 4) CS treatment significantly (P < .01) reduced the number of eosinophils and their MMP and TIMP-1 immunoreactive expression. CONCLUSIONS: CS treatment modulates NP mucosa remodeling, particularly by promoting epithelial repair, regulating tissue remodeling markers, increasing total collagen content, and reducing tissue eosinophil infiltration. LEVEL OF EVIDENCE: 4
Am J Rhinol Allergy. 2013
J Allergy Clin Immunol. 2014-12-4
J Allergy Clin Immunol. 2015-2-25
Front Med (Lausanne). 2023-4-17
Int Arch Otorhinolaryngol. 2022-12-19
Int J Physiol Pathophysiol Pharmacol. 2022-8-15
J Allergy Clin Immunol. 2020-6
Allergy Asthma Immunol Res. 2019-7
Cytokine Growth Factor Rev. 2019-5-10